Table 3.
Univariate analysis of prognostic factors for progression-free survival and overall survival (n=99)
| Variable | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age | ||||
| ≥50 years | 1 | 1 | ||
| <50 years | 1.34 (0.86–2.09) | 0.198 | 1.26 (0.81–1.96) | 0.310 |
| Size of the cervical tumor | ||||
| ≥4-cm | 1 | 1 | ||
| <4-cm | 0.86 (0.52–1.42) | 0.541 | 0.86 (0.52–1.43) | 0.554 |
| Histological subtype | ||||
| SCC | 1 | 1 | ||
| Non-SCC | 1.39 (0.81–2.38) | 0.234 | 1.86 (1.08–3.21) | 0.026 |
| ECOG PS | ||||
| 0–2 | 1 | 1 | ||
| 3–4 | 4.14 (2.52–6.79) | <0.001 | 3.29 (2.04–5.32) | <0.001 |
| Oligometastasis | ||||
| Yes | 1 | 1 | ||
| No | 2.10 (1.32–3.35) | 0.002 | 2.04 (1.28–3.24) | 0.003 |
| Bone metastasis | ||||
| Yes | 1 | 1 | ||
| No | 1.72 (1.10–2.67) | 0.017 | 1.74 (1.13–2.70) | 0.013 |
| Number of organ metastasis | ||||
| Single | 1 | 1 | ||
| Multiple | 1.58 (0.95–2.62) | 0.08 | 1.89 (1.13–3.17) | 0.016 |
| Lung metastasis | ||||
| Yes | 1 | 1 | ||
| No | 0.62 (0.40–0.96) | 0.033 | 0.66 (0.43–1.02) | 0.060 |
| Liver metastasis | ||||
| Yes | 1 | 1 | ||
| No | 0.48 (0.30–0.76) | 0.002 | 0.39 (0.24–0.62) | <0.001 |
| Distant lymph node metastasis | ||||
| Yes | 1 | 1 | ||
| No | 0.66 (0.43–1.02) | 0.061 | 0.65 (0.42–1.01) | 0.050 |
| Initial treatment | ||||
| Supportive care | 1 | 1 | ||
| Chemotherapy + local treatment | 0.27 (0.16–0.45) | <0.001 | 0.31 (0.18–0.53) | <0.001 |
| Chemotherapy | 0.52 (0.27–1.02) | 0.056 | 0.74 (0.38–1.44) | 0.378 |
| Radiotherapy | 1.29 (0.62–2.68) | 0.499 | 0.98 (0.48–2.03) | 0.973 |
Abbreviations: SCC, Squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.